Medical Communications

Showing 15 posts of 6411 posts found.

Living with Behçet’s disease

July 30, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Behçet's disease, patient experience, pharma

Suzanne Morris speaks to Pharmafocus to discuss her life with Behçet’s disease, a rare condition characterised by the inflammation of …
sean-harper

Amgen announces resignation of two top executives

July 27, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Anthony C Cooper, R&D, biotech, retire, sean harper

Amgen’s head of R&D, Dr Sean Harper, has announced that he is retiring from his current position as Executive Vice …
32514377531_3583dbc34b_z

Those at risk of HIV to be offered PrEP drugs in England and Northern Ireland

July 27, 2018 Medical Communications AIDS, England, HIV, PrEP, Terrence Higgins Trust

Those at risk of contracting HIV will now be offered PrEP drugs in England and Northern Ireland through a programme …
takeda_usa_pharmaceuticals_u

Takeda’s Alunbrig topples Pfizer’s Xalkori in ALK-positive lung cancer

July 27, 2018 Medical Communications, Research and Development Alunbrig, Cancer, NSCLC, Pfizer, Takeda, Xalkori, lung cancer, pharma

Takeda has unveiled new Phase 3 data showing that its tyrosine kinase inhibitor (TKI) Alunbrig (brigatinib) not only met its …
Canary Wharf European Medicines Agency

Landlord demands EMA pay £500m for Canary Wharf lease

July 27, 2018 Medical Communications Canary Wharf, EMA, Litigation, London, amsterdam, court

A British landlord is taking the European Medicines Agency (EMA) to court over a £500 million bill for unpaid rent. …
Scientist looking at medicinal cannabis in a laboratory

Cannabis-derived medicinal products to become available in UK

July 26, 2018 Medical Communications cannabis, law, medicinal marijuana, prescription, sajid javid, schedule drugs, uk politics

Home Secretary Sajid Javid has announced that cannabis derived medicinal products will be made available on prescription “by the autumn” …

Gilead’s CEO and Chairman to both step down before year’s end

July 26, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, pharma

Gilead has announced that its President and Chief Executive Officer Dr John Milligan (pictured) will be stepping down by the …
Matt Hancock

NHS to stockpile drugs in preparation for no-deal Brexit

July 25, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, brexit, government, pharma, stockpiling

Secretary of State for Health and Social Care, Matt Hancock, has said that the NHS is preparing to stockpile medicines …
stana-moisescu-appointment

Teva Romania announces new general manager

July 24, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Israeli multinational Teva Pharmaceuticals have announced the appointment of Stana Moisescu as the General Director of Teva Romania, the company’s …
512px-antibiotic_sensitvity_and_resistance

The mission against antimicrobial resistance

July 23, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing antibiotic resistance, antimicrobial resistance, feature, pharma

Two headlines have highlighted the ‘here and now’ of the threat of rising antimicrobial resistance (AMR), writes Dr Peter Jackson.A …
top_10_image

Top Ten most popular articles on Pharmafile.com this week

July 20, 2018 Medical Communications GSK, ICR, J&J, JJ, Novartis, Trump, brexit, top 10

As Brexit negotions have hit a stalemate this week, the United Kingdom’s exit from the European Union has hit the …
ki67-tubulin-2

Scottish borders-based Ryboquinn acquires viral delivery comany Nanogenics

July 20, 2018 Medical Communications M&A, MA, Scotland, acquisitions, gene therapy, nanogenics, ryboquinn

The Scottish biotech company Ryboquinn has acquired English partner Nanogenics Solutions in a deal worth £4.45 million. The Selkirk-based firm …
The Gateway to Local Adoption Series

Latest content